HALO vs. TEM: Halozyme Therapeutics vs. Tempus AI Stock Comparison

Company Profile

Halozyme Therapeutics (HALO) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but HALO is classified in Biotechnology while TEM is classified in Life Sciences Tools & Services.

Halozyme Therapeutics (HALO) carries decades of public-market history since March 16, 2004, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the HALO side.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) carries a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, whereas Halozyme Therapeutics (HALO) is closer to market-like at 0.96 — a noticeable difference in market-sensitivity profile.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Halozyme Therapeutics (HALO) reports 216.38%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Halozyme Therapeutics (HALO) reports 26.93%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Halozyme Therapeutics (HALO) reports 59.84%, ranking against industry peers normally.

Profitability Metrics

Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Halozyme Therapeutics (HALO) at 37.55% is closer to the peer norm — faster top-line expansion for TEM.

Only one side can be read here: Halozyme Therapeutics (HALO) reports EPS growth of -25.36%, ranked against its industry; Tempus AI (TEM) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Halozyme Therapeutics (HALO) at 3.88 and Tempus AI (TEM) at 2.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Only one side’s leverage can be read here: Tempus AI (TEM) carries debt-to-equity ratio of 2.86 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

Financial Strength Metrics

Dividends

Neither Halozyme Therapeutics (HALO) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Halozyme Therapeutics (HALO) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Halozyme Therapeutics (HALO) trades at 25.91 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.

On P/S ratio, both Halozyme Therapeutics (HALO) at 6.55 and Tempus AI (TEM) at 9.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Tempus AI (TEM) reports 27.66, ranking against industry peers normally.

Valuation Metrics